ISRCTN30820196 https://doi.org/10.1186/ISRCTN30820196

Living Well with Lung Cancer

Submission date	Recruitment status	[ ] Prospectively registered
12/05/2010	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
12/05/2010	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
29/03/2022	Cancer	[ ] Record updated in last year

Plain English summary of protocol
http://www.cancerhelp.org.uk/trials/a-study-of-follow-up-care-after-treatment-for-lung-cancer

Contact information

Type(s)
Scientific

Contact name
Dr Lynn Calman

Contact details
MRC Research Fellow
School of Nursing, Midwifery and Social Work
The University of Manchester
Jean McFarlane Building
University Place
Oxford Road
Manchester
United Kingdom
M13 9PL

Additional identifiers

Protocol serial number
6073; MRC G0601695

Study information

Scientific Title
Living well with lung cancer: evaluating the effectiveness of a sustainable model of follow-up care

Study objectives
Aims:
1. To develop a sustainable model of follow-up service delivery
2. To determine if the model is potentially beneficial (proof of concept) through an exploratory (feasibility) trial with outcomes focused on quality of life, patient satisfaction and cost effectiveness

Ethics approval required
Old ethics approval format

Ethics approval(s)
South Manchester Research Ethics Committee, 24/06/2009, ref: 09/H1003/72

Study design
Multicentre observational process of care qualitative study

Primary study design
Observational

Study type(s)
Quality of life

Health condition(s) or problem(s) studied
Topic: National Cancer Research Network; Subtopic: Lung Cancer; Disease: Lung (small cell), Lung (non-small cell)

Interventions
Stage one: developing the intervention -
In order to develop a robust evidence based intervention this project is designed using steps of the MRC framework for developing and evaluating complex interventions (MRC 2000/2007). The first stage of this framework is to develop the intervention using primarily qualitative methods, once the intervention has been developed a feasibility trial will be designed.

Intervention Type
Other

Phase
Not Applicable

Primary outcome(s)
1. Quality of life
2. Symptom control
3. Patient satisfaction

Key secondary outcome(s))
1. Survival
2. Economic evaluation

Completion date
30/04/2011

Eligibility

Key inclusion criteria
1. Completed initial treatment for lung cancer
2. Suitable for nurse-led follow-up (as defined in Stage 1)
3. Physically and psychologically able and willing to complete outcome measures
4. Not taking part in any other clinical trial
5. Age restrictions will not be imposed, both male and female participants will be recruited

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Total final enrolment
31

Key exclusion criteria
Patients with a diagnosis of mesothelioma will be excluded at this stage due to complexities of disease management.

Date of first enrolment
01/11/2009

Date of final enrolment
30/04/2011

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
MRC Research Fellow
Manchester
United Kingdom
M13 9PL

Sponsor information

Organisation
University of Manchester (UK)

ROR
https://ror.org/027m9bs27

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK) (ref: G0601695)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Plain English results		08/01/2014	29/03/2022	No	Yes